Pancreatic Ductal Adenocarcinoma Clinical Trials, Emerging Drugs and Pipeline Outlook 2024 (Updated)

DelveInsight's, "Pancreatic Ductal Adenocarcinoma Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the Pancreatic Ductal Adenocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Ductal Adenocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report
• DelveInsight's Pancreatic Ductal Adenocarcinoma Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma.
• The leading companies working in the Pancreatic Ductal Adenocarcinoma Market include Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others are evaluating new drugs for pancreatic ductal adenocarcinoma to improve the treatment landscape.
• Promising Pancreatic Ductal Adenocarcinoma Pipeline therapies include Mitazalimab, Onvansertib, NIS793, KN046, CAN04, NLM-001, Immuncell-LC, OSE2101, YH003, SBP-101, JPI-547, ELI-002, CEND-1, siG12D-LODER, AMP945, BMS-813160, CAN04, RMC-6236, AB122, GEN1042, DCC-3116, NGM707, AMT-151, SGN-CD228A, PEN-866, TJ033721, INCB106385, ZB131, BR55, CEND-1, BAY2287411, SD-101, JAB-21822, CM24, and others.
• March 2024: Jiangsu Alphamab Biopharmaceuticals Co., Ltd announced a study of Phase 3 clinical trials for KN046. This study is a multicenter, randomized, double-Blind Phase III Study to compare the clinical efficacy and safety of KN046 plus gemcitabine and nab-paclitaxel versus placebo plus gemcitabine and nab-paclitaxel in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.
• March 2024: Phanes Therapeutics announced a study of Phase 1 & 2 clinical trials for PT886, Paclitaxel and Gemcitabine. This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PT886. Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, and pancreatic ductal adenocarcinoma (PDAC).

Request a sample and discover the recent advances in Pancreatic Ductal Adenocarcinoma Treatment Drugs @ Pancreatic Ductal Adenocarcinoma Pipeline Report- https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Pancreatic Ductal Adenocarcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Ductal Adenocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Pancreatic Ductal Adenocarcinoma Overview
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis. PDAC development is associated with a poor prognosis due to its complicated and multifactorial nature.

Find out more about Pancreatic Ductal Adenocarcinoma Treatment Landscape @ Drugs for Pancreatic Ductal Adenocarcinoma Treatment- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Ductal Adenocarcinoma Emerging Drugs Profile
• Onvansertib: Cardiff Oncology
• Nadunolimab: Cantargia
• Zimberelimab: Arcus Biosciences

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment
There are approx. 80+ key companies which are developing the therapies Pancreatic Ductal Adenocarcinoma. The Pancreatic Ductal Adenocarcinoma companies which have their Pancreatic Ductal Adenocarcinoma drug candidates in the most advanced stage, i.e phase III include XOMA.

DelveInsight's Pancreatic Ductal Adenocarcinoma pipeline report covers around 80+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Pancreatic Ductal Adenocarcinoma Pipeline Therapies @ Pancreatic Ductal Adenocarcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report
• Coverage- Global
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Pancreatic Ductal Adenocarcinoma Companies- Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.
• Pancreatic Ductal Adenocarcinoma Pipeline Therapies- Mitazalimab, Onvansertib, NIS793, KN046, CAN04, NLM-001, Immuncell-LC, OSE2101, YH003, SBP-101, JPI-547, ELI-002, CEND-1, siG12D-LODER, AMP945, BMS-813160, CAN04, RMC-6236, AB122, GEN1042, DCC-3116, NGM707, AMT-151, SGN-CD228A, PEN-866, TJ033721, INCB106385, ZB131, BR55, CEND-1, BAY2287411, SD-101, JAB-21822, CM24, and others.

Dive deep into rich insights for new drugs for Pancreatic Ductal Adenocarcinoma treatment, Visit @ Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Pancreatic Ductal Adenocarcinoma Executive Summary
3. Pancreatic Ductal Adenocarcinoma: Overview
4. Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics
5. Pancreatic Ductal Adenocarcinoma Therapeutic Assessment
6. Pancreatic Ductal Adenocarcinoma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. NIS 793: XOMA
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CEND 1: Cend Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. DCC-3116: Deciphera Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. RMC-6236: REVOLUTION Medicines
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pancreatic Ductal Adenocarcinoma Key Companies
21. Pancreatic Ductal Adenocarcinoma Key Products
22. Pancreatic Ductal Adenocarcinoma- Unmet Needs
23. Pancreatic Ductal Adenocarcinoma- Market Drivers and Barriers
24. Pancreatic Ductal Adenocarcinoma- Future Perspectives and Conclusion
25. Pancreatic Ductal Adenocarcinoma Analyst Views
26. Pancreatic Ductal Adenocarcinoma Key Companies
27. Appendix

For further information on the Pancreatic Ductal Adenocarcinoma pipeline therapeutics, reach out @ Pancreatic Ductal Adenocarcinoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Other Important Links-

Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Vulvar Cancer Market- https://www.delveinsight.com/report-store/vulvar-cancer-market
Vascular Grafts Market- https://www.delveinsight.com/report-store/vascular-grafts-market
Acne Vulgaris Market- https://www.delveinsight.com/report-store/acne-vulgaris-av-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Angiofibroma Market- https://www.delveinsight.com/report-store/angiofibroma-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Ascites Market- https://www.delveinsight.com/report-store/ascites-market
Systemic Lupus Erythematosus Market- https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market
Post Operative Pain Management Market- https://www.delveinsight.com/report-store/post-operative-pain-management-market
Cxcr Inhibitors Market- https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
Androgen Receptor Inhibitor Market- https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
STS Devices Market- https://www.delveinsight.com/report-store/sts-devices-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.